GlassScriptPhysician profile
Madison Niederer
NPI 1245011881
$1,634.92
in general payments reported to CMS, 2019-2025
27 companies · $756 in 2025
The $756 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.34 · 2024: $800 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549 · Education: $86.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.70 |
| Education | $86.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.22 | 2023-2025 | Fruzaqla, Iclusig, Vpriv |
| Merck Sharp & Dohme LLC | $115.01 | 2023-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $106.75 | 2024-2025 | Imfinzi, Calquence, Onglyza |
| Pfizer INC. | $98.91 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $98.75 | 2024-2025 | Onivyde, Tazverik |
| Novartis Pharmaceuticals Corporation | $97.20 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $93.35 | 2024-2025 | |
| Lilly USA, LLC | $84.96 | 2023-2025 | Verzenio, Jaypirca |
| Eisai INC. | $82.62 | 2024-2025 | |
| Springworks Therapeutics, INC. | $81.26 | 2024-2025 | Ogsiveo |
| Incyte Corporation | $69.99 | 2024 | |
| Sumitomo Pharma America, INC. | $58.48 | 2024-2025 | Orgovyx |
| Janssen Biotech, INC. | $45.81 | 2024 | Talvey, Tecvayli |
| Emd Serono, INC. | $42.98 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $34.47 | 2024-2025 | Orserdu |
| Genentech USA, INC. | $31.51 | 2025 | Itovebi, Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.93 | 2025 | |
| Geron Corporation | $27.60 | 2025 | Rytelo |
| Genmab U.S., INC. | $26.64 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $25.85 | 2024 | |
| Agios Pharmaceuticals, INC. | $22.89 | 2025 | Pyrukynd |
| Coherus Oncology, INC. | $21.32 | 2024 | |
| Puma Biotechnology, INC. | $21.22 | 2024 | |
| Genzyme Corporation | $20.22 | 2024 | |
| Tersera Therapeutics LLC | $18.97 | 2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $17.61 | 2025 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Niederer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.